EUVIMEDSkopri EUVIMED
Klinische Studie (Phase II)Open access · CC BY-NC-ND 4.0

Phase II study of 131 I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP

François Sevrin iD, Hélène Kolesnikov-Gauthier, Olivier Cougnenc, Emilie Bogart, Gudrun Schleiermacher iD, Frederic Courbon, Marion Gambart, Anne-Laure Giraudet, Nadège Corradini, Jean-Noël Badel, Erwann Rault, Aurore Oudoux and 3 more

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30615 ↗

At a glance

Klinische Studie (Phase II) in Pediatric Blood & Cancer, 2023. Written by François Sevrin and 14 co-authors. Institution: Department of Pediatric Oncology, Oscar Lambret Center, Lille, France. Major MEDLINE topics: Neuroblastoma, Topotecan. Cited 15 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Institut National Du Cancer.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Purpose

We report the results of the French multicentric phase II study MIITOP (NCT00960739), which evaluated tandem infusions of 131 I‐metaiodobenzylguanidine (mIBG) and topotecan in children with relapsed/refractory metastatic neuroblastoma (NBL).

Methods

Patients received 131 I‐mIBG on day 1, with intravenous topotecan daily on days 1–5. A second activity of 131 I‐mIBG was given on day 21 to deliver a whole‐body radiation dose of 4 Gy, combined with a second course of topotecan on days 21–25. Peripheral blood stem cells were infused on day 31.

Results

Thirty patients were enrolled from November 2008 to June 2015. Median age at diagnosis was 5.5 years (2–20). Twenty‐one had very high‐risk NBL (VHR‐NBL), that is, stage 4 NBL at diagnosis or at relapse, with insufficient response (i.e., less than a partial response of metastases and more than three mIBG spots) after induction chemotherapy; nine had progressive metastatic relapse. Median Curie score at inclusion was 6 (1–26). Median number of prior lines of treatment was 3 (1–7). Objective response rate was 13% (95% confidence interval [CI]: 4–31) for the whole population, 19% for VHR‐NBL, and 0% for progressive relapses. Immediate tolerance was good, with nonhematologic toxicity limited to grade‐2 nausea/vomiting in eight patients. Two‐year event‐free survival was 17% (95% CI: 6–32). Among the 16 patients with VHR‐NBL who had not received prior myeloablative busulfan‐melphalan consolidation, 13 had at least stable disease after MIITOP; 11 subsequently received busulfan‐melphalan; four of them were alive (median follow‐up: 7 years).

Conclusion

MIITOP showed acceptable tolerability in this heavily pretreated population and encouraging survival rates in VHR‐NBL when followed by busulfan‐melphalan.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaTopotecanAdolescentChildChild, PreschoolHumansYoung Adult3-IodobenzylguanidineBusulfanChronic DiseaseMelphalanNeoplasm Recurrence, Local

Author keywords

131I-mIBG therapyneuroblastomatopotecan

Substances

3-IodobenzylguanidineBusulfanMelphalanTopotecan

Authors and institutions

  • Department of Pediatric Oncology, Oscar Lambret Center, Lille, France.
  • Department of Nuclear Medicine, Oscar Lambret Center, Lille, France.
  • Department of Clinical Pharmacy, Oscar Lambret Center, Lille, France.
  • Department of Methodology and Biostatistics, Oscar Lambret Center, Lille, France.
  • SIREDO Integrated Pediatric Oncology Center, Institut Curie, Paris, France.
  • Service de Médecine Nucléaire, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.

ORCID profiles: François Sevrin, Gudrun Schleiermacher, Anne-Sophie Defachelles

Funding

  • Institut National Du Cancer

Cite

APA

Sevrin, F., Kolesnikov-Gauthier, H., Cougnenc, O., Bogart, E., Schleiermacher, G., Courbon, F., Gambart, M., Giraudet, A. L., Corradini, N., Badel, J. N., Rault, E., Oudoux, A., Deley, M. C. L., Valteau-Couanet, D., & Defachelles, A. S. (2023). Phase II study of 131 I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30615

Vancouver

Sevrin F, Kolesnikov-Gauthier H, Cougnenc O, Bogart E, Schleiermacher G, Courbon F, et al. Phase II study of 131 I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30615

BibTeX
@article{Sevrin2023,
  author = {Sevrin, François and Kolesnikov-Gauthier, Hélène and Cougnenc, Olivier and Bogart, Emilie and Schleiermacher, Gudrun and Courbon, Frederic and Gambart, Marion and Giraudet, Anne-Laure and Corradini, Nadège and Badel, Jean-Noël and Rault, Erwann and Oudoux, Aurore and Deley, Marie Cécile Le and Valteau-Couanet, Dominique and Defachelles, Anne-Sophie},
  title = {Phase II study of 131 I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30615}
}
Start for free →